Where does Galaxy Biotech, LLC rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Galaxy Biotech, LLC ranks #40,355 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Galaxy Biotech, LLC hold?

Galaxy Biotech, LLC holds 6 US utility patents granted between 2016 and 2024, spanning 4 technology areas.

What is Galaxy Biotech, LLC's Innovation Score?

Galaxy Biotech, LLC has an Innovation Score of 24.1 out of 100 (14th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Galaxy Biotech, LLC focus on?

Galaxy Biotech, LLC's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 6 patents, ranking #2,984 of 6,058 assignees active in that subclass. Grants appear in 4 CPC subclasses total.

Is Galaxy Biotech, LLC's patent grant rate increasing or decreasing?

Galaxy Biotech, LLC's recent grant velocity is +0% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Galaxy Biotech, LLC's patents?

Galaxy Biotech, LLC's patents average 11.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Galaxy Biotech, LLC patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Galaxy Biotech, LLC

USPTO PatentsView assignee record - 6 granted patents across 4 technology areas, recorded in grant years 2016–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Galaxy ranks #40,355 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 4 technology areas.

#40,355
of 49,997 US assignees by volume: 14th percentile
by Innovation Score (24.1/100): 11.7
avg claims per patent: +0%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R40355 · US Corporation #40,355 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-USCORP · VEL-FLAT · BOOK-FULL

GRANTS-MICRO 6 grants
LOWER-Q #40,355/49,997
PHOTO-FINISH G2 Research
CPC-NARROW A61P · 4 areas
INNOV-THIN 24.1/100
CLAIMS-PAR 11.7 claims/avg
TYPE-USCORP US Corporation
VEL-FLAT +0% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: G2 Research Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Galaxy’s 24.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 6.7 pts (28%) Velocity 3.3 pts (14%) Breadth 7.1 pts (29%) Claim depth 7.0 pts (29%)

Qualcomm Incorporated · highest

85
Galaxy Biotech · this assignee

24
3D Lighting… · lowest

7

What this shows Galaxy's Innovation Score is 24.1/100 (14th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Galaxy?

Each dot is one of Galaxy’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Galaxy’s own 11.7 claims/patent is at or below the 12.7 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Galaxy vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Galaxy's grants concentrate

Galaxy Biotech, LLC is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). By volume, Galaxy sits between G2 Research Inc. and Galomb, Inc..

Galaxy's three-year grant acceleration

Galaxy Biotech, LLC shows 1 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

G2 Research

6
Gaba Internationa…

6
Gaboss Internatio…

6
Galata Chemicals

6
Galil Medical

6
Gallant Micro Mac…

6
Galmed Research A…

6
Galomb

6
Galaxy Biotech ◀

6

What this shows Galaxy holds 6 patents at rank #40,342, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Galaxy

By rank, the assignees closest to #40,342 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Galaxy's primary technology class.

Galaxy's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

24 14th percentile higher than 14% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Galaxy Biotech, LLC patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	1	16.7%
2017	1	16.7%
2018	1	16.7%
2020	1	16.7%
2021	1	16.7%
2024	1	16.7%

Which technologies does Galaxy Biotech, LLC patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 6

C07K - Peptides 6

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 6

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 4

Top 4 of 4 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Galaxy Biotech, LLC's patent record in context - here's where to go next.

Galaxy Biotech, LLC's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #40,355 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Galaxy Biotech, LLC against G2 Research Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 24.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.